10% Off $75 Orders! Use Code SAVE10P Shop Now
One use per customer. Not available with Autoship. Expires 5/28/18.

FDA MedWatch – New recommendations for use of Procrit in its cancer chemotherapy indication

1 Star2 Stars3 Stars4 Stars5 Stars (97 votes, average: 2.95 out of 5)
Loading...

MedWatch – The FDA Safety Information and Adverse Event Reporting Program Ortho Biotech Products notified healthcare professionals of important changes to the safety information and dosing sections of the product labeling for Procrit. To ensure consistency with labeling for other products in this class, changes to hemoglobin rate of rise and target were made. The new prescribing information recommends that the target hemoglobin in patients with cancer should not exceed 12 grams per deciliter in men and women. Read the MedWatch 2004 safety summary, including links to the "Dear Healthcare Professional" letter and the revised label, at: http://www.fda.gov/medwatch/SAFETY/2004/safety04.htm#procrit

1 Star2 Stars3 Stars4 Stars5 Stars (97 votes, average: 2.95 out of 5)
Loading...



Leave a Reply